Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 183

2.

[Lopinavir/ritonavir in new initial antiretroviral treatment strategies].

Rolón MJ, Figueroa MI, Sued O, Cahn P.

Enferm Infecc Microbiol Clin. 2014 Nov;32 Suppl 3:7-11. doi: 10.1016/S0213-005X(14)70161-2. Spanish.

PMID:
25542869
3.

Host genetic factors associated with symptomatic primary HIV infection and disease progression among Argentinean seroconverters.

Coloccini RS, Dilernia D, Ghiglione Y, Turk G, Laufer N, Rubio A, Socías ME, Figueroa MI, Sued O, Cahn P, Salomón H, Mangano A, Pando MÁ.

PLoS One. 2014 Nov 18;9(11):e113146. doi: 10.1371/journal.pone.0113146. eCollection 2014.

4.

Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicity.

Patterson P, Socías E, Pryluka D, Lapadula P, Pérez H, Cahn P.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19794. doi: 10.7448/IAS.17.4.19794. eCollection 2014.

5.

Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL study.

Cahn P, Villanueva JA, Arribas J, Gatell J, Lama J, Norton M, Patterson P, Madero JS, Sued O, Figueroa MI, Rolón MJ.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19554. doi: 10.7448/IAS.17.4.19554. eCollection 2014.

6.

Factors associated with healthcare avoidance among transgender women in Argentina.

Socías ME, Marshall BD, Arístegui I, Romero M, Cahn P, Kerr T, Sued O.

Int J Equity Health. 2014 Sep 27;13(1):81. doi: 10.1186/s12939-014-0081-7.

7.

Use of third line antiretroviral therapy in Latin America.

Cesar C, Shepherd BE, Jenkins CA, Ghidinelli M, Castro JL, Veloso VG, Cortes CP, Padgett D, Crabtree-Ramirez B, Gotuzzo E, Fink V, Duran A, Sued O, McGowan CC, Cahn P; Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet).

PLoS One. 2014 Sep 15;9(9):e106887. doi: 10.1371/journal.pone.0106887. eCollection 2014.

8.

Early skewed distribution of total and HIV-specific CD8+ T-cell memory phenotypes during primary HIV infection is related to reduced antiviral activity and faster disease progression.

Ghiglione Y, Falivene J, Ruiz MJ, Laufer N, Socías ME, Cahn P, Giavedoni L, Sued O, Gherardi MM, Salomón H, Turk G.

PLoS One. 2014 Aug 5;9(8):e104235. doi: 10.1371/journal.pone.0104235. eCollection 2014.

9.

MicroRNAs differentially present in the plasma of HIV elite controllers reduce HIV infection in vitro.

Reynoso R, Laufer N, Hackl M, Skalicky S, Monteforte R, Turk G, Carobene M, Quarleri J, Cahn P, Werner R, Stoiber H, Grillari-Voglauer R, Grillari J.

Sci Rep. 2014 Aug 1;4:5915. doi: 10.1038/srep05915.

10.

Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, Burger DM, Cahn P, Gallant JE, Glesby MJ, Reiss P, Saag MS, Thomas DL, Jacobsen DM, Volberding PA; International Antiviral Society-USA Panel.

JAMA. 2014 Jul 23-30;312(4):410-25. doi: 10.1001/jama.2014.8722.

PMID:
25038359
11.

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.

Cahn P, Andrade-Villanueva J, Arribas JR, Gatell JM, Lama JR, Norton M, Patterson P, Sierra Madero J, Sued O, Figueroa MI, Rolon MJ; GARDEL Study Group.

Lancet Infect Dis. 2014 Jul;14(7):572-80. doi: 10.1016/S1473-3099(14)70736-4. Epub 2014 Apr 27.

PMID:
24783988
12.

Treatment as prevention: are Argentinean HIV care providers willing to adopt earlier antiretroviral therapy?

Socías ME, Sued O, Pryluka D, Patterson P, Fink V, Cesar C, Cahn P.

AIDS Care. 2014;26(11):1446-51. doi: 10.1080/09540121.2014.915286. Epub 2014 Apr 29.

PMID:
24773142
13.

Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.

Tudor-Williams G, Cahn P, Chokephaibulkit K, Fourie J, Karatzios C, Dincq S, Opsomer M, Kakuda TN, Nijs S, Tambuyzer L, Tomaka FL; PIANO study group.

HIV Med. 2014 Oct;15(9):513-24. doi: 10.1111/hiv.12141. Epub 2014 Mar 3.

PMID:
24589294
14.

In and out of the curriculum: an historical case study in implementing interprofessional education.

Cahn PS.

J Interprof Care. 2014 Mar;28(2):128-33. doi: 10.3109/13561820.2013.872607. Epub 2014 Jan 2.

PMID:
24383409
15.

Patient-provider perceptions on engagement in HIV care in Argentina.

Bofill LM, Lopez M, Dorigo A, Bordato A, Lucas M, Cabanillas GF, Sued O, Cahn P, Cassetti I, Weiss S, Jones D.

AIDS Care. 2014;26(5):602-7. doi: 10.1080/09540121.2013.844767. Epub 2013 Oct 21.

16.

Efficacy and safety of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents: 5 years of experience.

Salazar JC, Cahn P, Della Negra M, De Aquino MZ, Robinson PA, Jelaska A, Mikl J.

Pediatr Infect Dis J. 2014 Apr;33(4):396-400. doi: 10.1097/INF.0000000000000038.

PMID:
23995585
17.

Routine HIV testing among hospitalized patients in Argentina. is it time for a policy change?

Socías ME, Hermida L, Singman M, Kulgis G, Díaz Armas A, Cando O, Sued O, Pérez H, Hermes R, Presas JL, Cahn P.

PLoS One. 2013 Jul 31;8(7):e69517. doi: 10.1371/journal.pone.0069517. Print 2013.

18.

Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria.

Nosyk B, Audoin B, Beyrer C, Cahn P, Granich R, Havlir D, Katabira E, Lange J, Lima VD, Patterson T, Strathdee SA, Williams B, Montaner J.

AIDS. 2013 Apr 24;27(7):1159-65. doi: 10.1097/QAD.0b013e32835f1d68. Review.

PMID:
23902921
19.

HIV enteropathy: HAART reduces HIV-induced stem cell hyperproliferation and crypt hypertrophy to normal in jejunal mucosa.

Batman PA, Kapembwa MS, Belmonte L, Tudor G, Kotler DP, Potten CS, Booth C, Cahn P, Griffin GE.

J Clin Pathol. 2014 Jan;67(1):14-8. doi: 10.1136/jclinpath-2012-201289. Epub 2013 Jul 23.

PMID:
23881223
20.

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S; extended SAILING Study Team.

Lancet. 2013 Aug 24;382(9893):700-8. doi: 10.1016/S0140-6736(13)61221-0. Epub 2013 Jul 3. Erratum in: Lancet. 2014 Jan 4;383(9911):30.

PMID:
23830355
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk